Compare Biogen Inc (BIIB) vs Pinterest Inc (PINS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Pinterest Inc — how do they compare? Biogen Inc trades at $193.97 (market cap $28.34B), while Pinterest Inc trades at $23.25 (market cap $12.66B). The key difference: Biogen Inc is far larger — about 2.2× Pinterest Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | PINS | |
|---|---|---|
Market Cap | $28.34B | $12.66B |
Sector | Health | Media |
52-Week High | $216.63 | $39.17 |
52-Week Low | $122.68 | $15.42 |
Enterprise Value | $30.62B | $12.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Pinterest (PINS) trades at $22.6, up 0.31% on the day, with a bullish technical outlook and strong analyst consensus. Revenue grew to $4.22B in 2025, with net income of $417M, though Q2 2026 earnings are pending. Recent news highlights AI-driven shopping features and user growth, supporting positive sentiment.
The stock offers upside to the $27.72 consensus target, but high valuation ratios and recent insider selling pose risks. Earnings consistency and competitive pressures in social media remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
